Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Français FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • Brazil
    • Canada
    • United States
    • Mexico
    • Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Romania
    • Hungary
    • Slovakia
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories

Post navigation

Previous
Next

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Attachment

  • Ipsen_Consolidated financial statements 2025_GB

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

- 19 February 2026 - 1 mins read

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Attachment

  • Ipsen_Consolidated financial statements 2025_GB

Post navigation

Previous
Next

Related Press Releases

10 August 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
03 August 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
30 July 2026

Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30...
29 July 2026

Ipsen nominates Catherine Bradley to its Board of Directors as...
27 July 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
24 July 2026

Ipsen provides update on Phase III BOLD trial in biliary...
22 July 2026

Ipsen – Corrective statement amending the monthly disclosure of the...
22 July 2026

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
21 July 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
15 July 2026

IPSEN – Buy-back programme – Art 5 of MAR –...

IPN price

€158.30

 €-3.30 (-2.04%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?